

# Predictive Oncology Featured in Publication Discussing the Impact of Artificial Intelligence on Cancer Treatment

November 6, 2019

NEW YORK, Nov. 06, 2019 (GLOBE NEWSWIRE) -- via NetworkWire —[Predictive Oncology \(NASDAQ: POAI\)](#) today announces its placement in an editorial published by [NetworkNewsWire](#) ("NNW"), a multifaceted financial news and publishing company for private and public entities.

To view the full publication, titled "New Hope in the Battle Against Ovarian Cancer," visit: <http://nnw.fm/ncA18>

Ovarian cancer is difficult to treat and lethal, with survival rates much lower than other cancers that affect women. Recently, the battle against ovarian cancer has shifted strategy, and new optimism has come to the fore.

Predictive models using artificial intelligence on large data sets of patient drug-treatment protocols and historical outcomes are now providing actionable intelligence for pharma to develop targeted therapeutics and for oncologists to prescribe the best course of treatment to improve individual patient outcomes. **Predictive Oncology (NASDAQ: POAI) (POAI Profile)** is laser focused on providing the molecular information critically needed to improve the lives of women stricken with ovarian cancer. The company has begun sequencing ovarian cancers as part of its CancerQuest2020 project and is building the largest ovarian multi-omic database in the world, designed to speed the development of new drugs and provide better therapeutic choices. The rest of pharma is also racing to find solutions.

## About Predictive Oncology Inc.

Predictive Oncology is an AI-driven company focused on applying artificial intelligence to personalized medicine and drug discovery. The company applies smart tumor profiling and its AI platform to extensive genomic and biomarker patient data sets to predict clinical outcomes and, most importantly, improve patient outcomes for cancer patients of today and tomorrow. Predictive Oncology currently has approximately 150,000 clinically validated cases on its molecular information platform, with more than 38,000 specific to ovarian cancer. The company's data is highly differentiated, having both drug-response data and access to historical outcome data from patients. Predictive Oncology intends to generate additional sequence data from these tumor samples to deliver on the clear unmet market need across the pharmaceutical industry for a multi-omic approach to new drug development. For more information, visit the company's website at [www.Predictive-Oncology.com](http://www.Predictive-Oncology.com).

## About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via [NetworkWire](#) to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets, (3) enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with [NNW Prime](#). As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today's market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge. For more information, please visit <https://www.NetworkNewsWire.com>.

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: <http://NNW.fm/Disclaimer>.

## Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

## Corporate Communications:

NetworkWire (NW)  
New York, New York  
[www.NetworkNewsWire.com](http://www.NetworkNewsWire.com)  
212.418.1217 Office  
[Editor@NetworkWire.com](mailto:Editor@NetworkWire.com)

Source: Predictive Oncology